Physician profile
Michael Park
NPI 1285997700
$3,186.32
in general payments reported to CMS, 2019-2025
34 companies · $858 in 2025
The $858 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.20 · 2020: $274 · 2021: $478 · 2022: $287 · 2023: $779 · 2024: $476 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.46 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $351.37 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $235.93 | 2022-2025 | |
| Abbvie INC. | $229.06 | 2021-2025 | |
| Gilead Sciences, INC. | $172.60 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.29 | 2020-2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $141.68 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $134.02 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $133.13 | 2020-2025 | |
| Inspire Medical Systems, INC. | $126.18 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $123.95 | 2025 | |
| Amgen INC. | $87.55 | 2019-2025 | Evenity |
| Astrazeneca Pharmaceuticals Lp | $81.79 | 2023-2025 | Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $80.96 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.55 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.79 | 2023-2024 | Rexulti, Jynarque |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.32 | 2020-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $43.49 | 2025 | General - Pain Management |
| Abbott Laboratories | $43.25 | 2022-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $40.79 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Viiv Healthcare Company | $40.74 | 2023-2024 | Apretude |
| Radius Health, INC. | $39.94 | 2020-2021 | |
| Hologic Sales and Service, LLC | $34.27 | 2022-2023 | Aptima |
| Eisai INC. | $31.13 | 2020 | |
| Shield Therapeutics INC | $20.03 | 2023 | Accrufer |
| Dexcom, INC. | $18.17 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.69 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $17.28 | 2021 | |
| Amarin Pharma, INC. | $16.87 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2021 | |
| Allergan, INC. | $15.00 | 2020 | |
| Dermira, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.